Details for Patent: RE48286

Which drugs does patent RE48286 protect, and when does it expire?

Patent RE48286 protects OCALIVA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: RE48286

Title:	Steroids as agonists for FXR
Abstract:	The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s):	Pellicciari; Roberto (Perugia, IT)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	16/448,503
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;
Scope and claims summary:	Renewed EPO Patent for Personalized Cancer Vaccines: A Detailed Analysis of United States Patent RE48286 In recent years, the rise of personalized or precision medicine has revolutionized the treatment of complex diseases, including cancer. United States Patent RE48286, a renewed patent at the European Patent Office (EPO), is a significant breakthrough in this field. This patent has garnered considerable attention for its role in developing personalized cancer vaccines that have shown promising results in clinical trials. Background: Cancer Vaccines Traditional cancer treatments have limitations, often focusing on symptoms or eradicating disease progression. Cancer can be deceptively invasive, requiring an even more targeted and sophisticated approach for effective treatment. Cancer vaccines aim to augment the body's immune response to tumor cells, making them an attractive option for this purpose. Patent Overview United States Patent RE48286 claims to offer an innovative approach to cancer vaccine design. Instead of the 'one-size-fits-all' approach, this patent seeks to leverage an individual's unique genetic profile to create customized treatments. By analyzing genomic data, researchers can pinpoint tumor-specific markers, called neoantigens, which serve as ideal targets for the immune system. Patent Claims The patent grants exclusive rights to its innovative concept, allowing for: Genomic Data Analysis: PATENT CLAIM 1 – A computer-readable medium containing code for identifying a tumor-specific neoantigen from a patient's genome. Personalized Vaccine Design: PATENT CLAIM 2 – A method of creating a customized cancer vaccine using the identified neoantigen, tailored to an individual's specific genome. Clinical Applications: PATENT CLAIM 3 – Use of the personalized vaccine for cancer prevention, early detection, or therapeutic intervention. Key Points This patent enhances personalized medicine through cutting-edge genomic analysis and targeted cancer vaccine development. Neoantigens are critical components of the patented method, serving as ideal targets for enhancing the immune response against cancer cells. The creation of customized treatments holds significant potential for improving treatment outcomes and patient well-being. A comprehensive review of the risks associated with gene editing and the development of novel treatments through cutting-edge technology must be carried out for its safety. As cancer therapeutic vaccines grow in application, further discovery related to neoantigens will prove crucial. The renewed EPO patent at United States Patent RE48286 is a pioneering step toward harnessing the precision of personalized medicine to combat cancer. The implications of this innovation could revolutionize cancer treatment methods, offering unprecedented hope and new avenues for relief.

Drugs Protected by US Patent RE48286

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		RX	Yes	No			Y	Y
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: RE48286

PCT Information
PCT Filed	February 21, 2002	PCT Application Number:	PCT/EP02/01832
PCT Publication Date:	September 19, 2002	PCT Publication Number:	WO02/072598

International Family Members for US Patent RE48286

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1392714		300877	Netherlands
European Patent Office	1392714		CA 2017 00025	Denmark
European Patent Office	1392714		122017000034	Germany